Salestools LogoSalestools
Salestools LogoSalestools
Biotech

Insitro

Insitro raises $400M Series D at $2.8B valuation

$400M
Total Raised
Series D
Latest Round
2018
Founded
300+
Employees
279 East Grand Avenue, South San Francisco, CA 94080
1 min read

Quick Facts

Valuation
$2.8B
Latest Round Size
$400M
Latest Round Date
September 2024

Insitro: Series D Funding Round

Insitro has successfully raised $400M in Series D funding, reaching a valuation of $2.8B.

Company Overview

Machine learning for drug discovery

Funding Details

The Series D round was led by Blackstone, with participation from Canada Pension Plan Investment Board, Arch Venture Partners, Foresite Capital, GV, Andreessen Horowitz.

Company Information

  • Headquarters: 279 East Grand Avenue, South San Francisco, CA 94080
  • Founded: 2018
  • Employees: 300+
  • Category: Biotech

Investment

Insitro plans to use the funds to accelerate product development, expand its team, and scale operations globally.

About the Investors

  • Blackstone: Verified investor in Series D
  • Canada Pension Plan Investment Board: Verified investor in Series D
  • Arch Venture Partners: Verified investor in Series D
  • Foresite Capital: Verified investor in Series D
  • GV: Verified investor in Series D
  • Andreessen Horowitz: Verified investor in Series D

Key Investors

Blackstone
Lead Investor
Verified investor in Series D
Canada Pension Plan Investment Board
Investor
Verified investor in Series D
Arch Venture Partners
Investor
Verified investor in Series D
Foresite Capital
Investor
Verified investor in Series D
GV
Investor
Verified investor in Series D
Andreessen Horowitz
Investor
Verified investor in Series D

Topics

verified(3079)real-funding(3079)insitrobiotechseries-d279-east-grand-avenue

About the Author

Editorial Team
Editorial Team
Curated funding news from verified sources

Related Company Reports

Biotech
Orna Therapeutics

Orna Therapeutics Raises $251M Series B

Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases

Emma Rodriguez
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics

Forge Biologics Raises $120M Series C

Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines

Sarah Kim
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology

Vir Biotechnology Raises $250M

Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza

Sarah Kim
Sarah Kim
Oct 23, 2025
0 min read•$250M